Patent intelligence · US
US 11964003
Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
Patent details — US 11964003
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 23, 2024
- Expiration
- Apr 18, 2044
- Applicant
- XERIS PHARMACEUTICALS, INC.
- Claims
- 47
- CPC classes
- A61K, A61K38/26, A61K47/02, A61K47/20
Quick answer
US 11964003 (Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same) is held by XERIS PHARMACEUTICALS, INC.. Status: granted. Granted Apr 23, 2024. Expires Apr 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- XERIS PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 47
- CPC classes
- A61K, A61K38/26, A61K47/02, A61K47/20, A61K47/34, A61K9/0019
More from XERIS PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12377096
Methods of treating disease with levoketoconazole
granted -
US 11957736
Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
granted -
US 11833157
Precipitation resistant small molecule drug formulations
granted -
US 11590205
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
granted -
US 11576951
Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
granted -
US 11446310
Stable formulations for parenteral injection of small molecule drugs
granted -
US 11129940
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
granted
Related coverage
Frequently asked questions
What is US patent 11964003?
US 11964003 (Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same) is held by XERIS PHARMACEUTICALS, INC.. Status: granted. Granted Apr 23, 2024. Expires Apr 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11964003?
XERIS PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does US 11964003 expire?
Our index shows an expiration date of Apr 18, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.